Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 31

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 31
---
 economic and market conditions affecting our healthcare diagnostics segment (MRNA Scientific Sdn. Bhd.) and our specialty chemicals segment (Chemrex Corporation Sdn. Bhd.); and initiatives such as contract development and manufacturing (CDMO) efforts and digital-asset treasury strategies. The foregoing list is not intended to be exhaustive.

All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements disclosed under “Risk Factors” in this prospectus, as such risk factors may be amended, supplemented or superseded from time to time by reports we file with the SEC, including subsequent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and in any prospectus supplement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this prospectus and in our other filings with the SEC that advise of the risks and factors that may affect our business.

Any forward-looking statement speaks only as of the date on which it is made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

| S-4 |

<div align='center'>PROSPECTUS SUPPLEMENT SUMMARY</div>

This summary contains basic information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before deciding to invest in our securities. Before you decide to invest in our securities, you should read this entire prospectus supplement and the accompanying prospectus carefully, any related free writing prospectus that we have authorized for use in connection with the offering and the documents incorporated by reference herein, including the information under the heading “Risk Factors.”

Overview

BioNexus Gene Lab Corp. (“BioNexus,” “BGLC,” the “Company,” “we,” “our,” or “us”) is a Wyoming corporation with operations primarily in Malaysia through two wholly owned subsidiaries: MRNA Scientific Sdn. Bhd. (“MRNA Scientific Malaysia”) and Chemrex Corporation Sdn. Bhd. (“Chemrex”). We operate across (i) healthcare diagnostics, focused on RNA-based liquid biopsy screening tests intended to enable early detection and risk assessment for certain diseases, and (ii) specialty chemicals distribution serving industrial customers in the ASEAN region. Our common stock is listed on The Nasdaq